{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=8",
    "query": {
      "condition": "First Line Therapy",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1005,
    "total_pages": 101,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T23:24:56.214Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04476329",
      "title": "Optimization for Regorafenib in HCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib 40 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SC Liver Research Consortium, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-01-21",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-30",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 9,
      "location_summary": "Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476329"
    },
    {
      "nct_id": "NCT01133977",
      "title": "E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2010-04",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-10-10",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 5,
      "location_summary": "Hagerstown, Maryland • Albany, New York • Greenville, South Carolina + 2 more",
      "locations": [
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01133977"
    },
    {
      "nct_id": "NCT05537402",
      "title": "LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab and bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "transarterial chemoembolization (TACE) or transarterial radioembolization (TARE",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2023-09-27",
      "completion_date": "2025-06-06",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05537402"
    },
    {
      "nct_id": "NCT04698681",
      "title": "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "Non-Squamous Non-Small Cell Neoplasm of Lung",
        "KEAP1 Gene Mutation",
        "NRF2 Mutation",
        "NFE2L2 Gene Mutation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-01-19",
      "completion_date": "2022-02-09",
      "has_results": false,
      "last_update_posted_date": "2023-03-13",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 63,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04698681"
    },
    {
      "nct_id": "NCT06842030",
      "title": "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Personalized Medicine",
        "Oligometastatic Disease",
        "Feasibility"
      ],
      "interventions": [
        {
          "name": "Darwin OncoTarget and OncoTreat",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Good Samaritan Hospital Medical Center, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-10",
      "completion_date": "2027-04-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 1,
      "location_summary": "West Islip, New York",
      "locations": [
        {
          "city": "West Islip",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06842030"
    },
    {
      "nct_id": "NCT03884101",
      "title": "Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Neoplasms"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 842,
      "start_date": "2019-04-11",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 29,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03884101"
    },
    {
      "nct_id": "NCT05607550",
      "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Lung Cancer",
        "EGFR Exon 20 Mutations"
      ],
      "interventions": [
        {
          "name": "furmonertinib 240 mg oral, daily",
          "type": "DRUG"
        },
        {
          "name": "furmonertinib 160 mg oral, daily",
          "type": "DRUG"
        },
        {
          "name": "platinum-based chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArriVent BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 398,
      "start_date": "2023-06-01",
      "completion_date": "2028-02-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 69,
      "location_summary": "Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05607550"
    },
    {
      "nct_id": "NCT06997497",
      "title": "A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Calderasib",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin/levofolinate calcium",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab biosimilar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 477,
      "start_date": "2025-07-16",
      "completion_date": "2030-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 43 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997497"
    },
    {
      "nct_id": "NCT00033514",
      "title": "Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2001-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033514"
    },
    {
      "nct_id": "NCT06487585",
      "title": "ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vasodilatory Hypotension During or After Cardiac Surgery"
      ],
      "interventions": [
        {
          "name": "Angiotensin II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland St. Joseph Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-06",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-20T23:24:56.214Z",
      "location_count": 1,
      "location_summary": "Towson, Maryland",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06487585"
    }
  ]
}